Introduction APS is an autoimmune disorder characterized by the presence of antiphospholipid antibodies (aPL) as well as clinical symptoms such as arterial and venous thrombosis and/or pregnancy complications. First determined in 1998, the international classification criteria have been updated in 2006 and are described in 1 Adverse pregnancy outcomes are various and can lead to high morbidity for both mother and fetus. 2, 3 aPL is a family of 3 types of antibodies that bind to the cell membrane: lupus anticoagulant, anticardiolipin (aCL) antibodies, and anti-β 2 -gl ycoprotein-1 (anti-β 2 GP1) antibodies. 4,5 Laboratory tests for the presence of aPL are still a matter of debate. Poor standardization of tests leads indeed to difficulties in interpretation of the results and, therefore, in difficulties in patient's management. 6,7 Research on the specific domains of According to the Euro-Phospholipid Project, deep-venous thrombosis is the main clinical feature found among APS patients. 16 Moreover, the Nimes Obstetricians and Hematologists APS (NOH-APS) study showed that purely obstetrical APS patients with no history of thromboembolic diseases (n = 517), had an increased risk of thrombosis including deep-venous thrombosis (1.46%), pulmonary embolism (PE, 0.43%), and superficial vein thrombosis (0.44%), despite low-dose aspirin treatment compared with controls (n = 796 with 0.43%, 0.12%, 0.14%, respectively). 19 This suggests that thrombotic mechanisms could be common to both obstetrical and nonobstetrical APS, although many other mechanisms have been proposed for the observed pregnancy complications (not the topic of this review paper). Therefore, general management of APS during pregnancy should also carefully include prevention of thrombosis (see Management of obstetrical APS).
Arterial thrombosis can also be associated with APS pregnancies. 20 Main clinical manifestations include strokes, transient ischemic attacks, and amaurosis fugax. In the NOH-APS study, cerebrovascular events were significantly higher in obstetrical APS patients compared with control patients (0.32% vs. 0.09%). 19, 20 Thrombocytopenia Autoimmune thrombocytopenia affects up to 20% to 30% of APS patients. Although it can be difficult to distinguish from idiopathic thrombocytopenia purpura (ITP), platelet count should be assessed prior to conception and throughout pregnancy. 16, 20 Moreover, as LMWH injections can sometimes induce a decrease in platelet count, some authors propose to follow platelet counts the first 3 weeks of treatment but this indication is not compulsory for others.
Cutaneous manifestations Skin conditions are frequent (36.9%) and various among APS patients. The most common is livedo reticularis, affecting around 20% of the patients. 21 It is more commonly found in secondary APS associated with SLE (36%) compared with primary APS (16%), and in women (26%) compared with men (16%). 22 We here describe both clinical and biological assessments of obstetrical APS. We do not deal with pathophysiological mechanisms of obstetrical APS but, on the contrary, we insist on its general management and therapeutic aspects. Finally, we discuss some therapeutic perspectives.
Epidemiology Even if aPL are found in 1% to 5% of the general population, the prevalence of APS is said to be no more than 0.5%. The Euro-Phospholipid project examined a cohort of 1000 patients diagnosed with APS and showed that there was a female-to-male ratio of 5:1. The majority of reported patients affected by APS were Caucasian (98.5%). 16 APS can equally be found alone ("isolated form" or "primary APS") or associated with other diseases, especially autoimmune diseases, systemic lupus erythematosus (SLE) being the main one (TABLE 2).
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Clinical aspects: when to think of APs during pregnancy? APS is an entity with various clinical aspects that can be difficult to diagnose, especially during pregnancy. We here describe the general clinical aspects of APS from the perspective of the mother and fetus and also some new considerations of APS regarding infertility and infants born from a mother with APS.
Clinical features for mother and fetus throughout pregnancy Medical complications: thrombosis Pregnancy in itself induces a hypercoagulable state, predisposing to thrombosis and particularly during postpartum period. Pregnant women have indeed a 5-to 6-fold increased risk of venous thrombosis compared with nonpregnant women of the same age. 18 affected 10.6% of live births. 22 A study conducted from 1990 to 1991 on 55 pregnant women with fetuses with intrauterine growth restriction (IUGR) defined as below the 10th percentile showed a strong association between fetal growth restriction and the presence of aCL. 27 Moreover, a critical review of the literature analyzed 3 prospective studies that investigated the prevalence of aPL among pregnant women with IUGR. The overall prevalence of aPL was 9.5% (interquartile range [IQR], 1.5-20.5). However, one of the main limitations of these studies was the definition of IUGR (birth weight lower than the 5th or 10th). 27
Preeclampsia and eclampsia Preterm delivery is commonly found in 20% of APS pregnancies and mostly owing to complications such as preeclampsia. 22 Preeclampsia is a common disorder that affects 8% of pregnancies. Its definition is purely clinical and described in TABLE 3. APS is considered a risk factor for severe preeclampsia, and studies show an increase in the prevalence of aPL in this specific population. 22 Moreover, in the Euro-Phospholipid Project, 9.5% of pregnant APS were diagnosed with preeclampsia, which was the most common feature found in mothers followed by eclampsia, which complicated 4.4% of pregnancies. 26 In a critical review of the literature conducted in 2013 based on the analysis of 20 papers, aPL was seen in 4% of the cases with preeclampsia, 8% of severe preeclampsia and 16.5% of eclampsia. 28 However, there are many limitations in this review with only 50% of studies implementing the term "severe preeclampsia" and a small sample size (median, 70; IQR 29-163). Moreover, the definition of "severe preeclampsia" was only specified in 50% of the studies. Regarding biological criteria, 60% of all papers were published prior 2000, meaning that anti-β 2 GP1 antibodies were not tested since they were not part of the APS definition until 2006. All 3 aPL assays were only performed in 11% of the studies. Moreover, it is now admitted that pregnant patients with a triple antiphospholipid antibody positivity are at a high risk of poor neonatal outcome.
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HELLP syndrome HELLP syndrome is a rare condition, the prevalence of which is still hard to estimate. It is usually secondary to preeclampsia, but can occur alone. A critical review of the literature show that only few studies have investigated the role of aPL in HELLP syndrome (n = 4). 29 Among them, the overall prevalence of aPL was 3% (CI 2-14.8) but this might have been misestimated due to the small sample size of patients.
Insights of some new clinical criteria of obstetrical
antiphospholipid syndrome The role of aPL in implantation and, therefore, the implications of aPL in infertility is still controversial. A critical assessment of the role of aPL in infertility show that although numerous studies on this subject have already been made, there is still no clear answer Leg ulcers (5.5%), pseudovasculitic lesions (3.9%), digital gangrene (3.3%), cutaneous necrosis (2.1%), and splinter hemorrhages (0.9%) can also be found. 22 Catastrophic antiphospholipid syndrome Catastrophic APS is a rare condition, defined as a "thrombotic storm", leading to multi-organ failure caused by recurrent thrombosis of large and small vessels and high aPL titers. 23 Among all precipitating factors (infections being the main ones), which are found in 50% of the cases, 5.6% are caused by obstetric conditions. Patients with preeclampsia and HELLP syndrome are indeed particularly at risk of catastrophic APS. 24 In a small retrospective series of 13 patients with pregnancy-related CAPS, CAPS usually followed HELLP syndrome (n = 12). 25 Therefore, clinicians should be very cautious about this potentially life-threatening condition especially when dealing with HELLP syndrome as CAPS can be lethal in about 50% of the cases. obstetrical complications Recurrent fetal loss and stillbirth A retrospective cohort study conducted from 1988 to 2006 on 1719 patients with unexplained recurrent miscarriages showed that there was no clear correlation between the number of preceding miscarriages and the age of the mother with APS diagnosis. However, once all risk factors for miscarriages were excluded, aPL were still responsible for 18% of recurrent miscarriages. 26 Early fetal loss is the most common fetal feature for obstetrical APS and affect around 35% of pregnancies. 22 Although quite uncommon in developed countries, stillbirth can occur in 16.9% of APS pregnancies.
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Prematurity and intrauterine growth restriction In the Euro-Phospholipid Project, prematurity 
a ≥30 mmHg or in DBP b ≥15 mmHg after 20 WG, with edema and/or proteinuria severe preeclampsia -presence of preeclampsia as described above and at least 1 of the following criteria: -SBP ≥160 mmHg, or DBP ≥110 mmHg on 2 occasions at least 6 h apart -proteinuria ≥5 g in a 24-h urine sample collected at least 4 h apart -pulmonary edema or cyanosis -oliguria (<400 ml in 24 h) -persistent headaches -epigastric pain and/or impaired liver function -thrombocytopenia -oligohydramnios, decreased fetal growth, or placental abruption Abbreviations: DBP -diastolic blood pressure, SBP -systolic blood pressure, others -see TABLE 1 Which test? Common aPL biological tests are described in 32 APL IgA have been shown to induce thrombosis in a mouse model. 33 However, the pathogenicity of aPL IgA in humans is still unclear. Recently, studies have shown that aCL and anti-β 2 GP1 IgA might be potentially interesting for the diagnosis of APS in Afro-Caribbean patients. 34 In this population, aPL IgA in APS secondary to SLE have been associated with an increase in thrombosis. 36 Antiphosphatidylethanolamine (aPE), antiphosphatidylserine (aPS), and anti-annexin-V antibodies have been specifically reported to increase pregnancy morbidity, aPE antibodies being associated with an increase in about the association between aPL and conception disorders in patients. 30 Therefore, testing for aPL in patients with a history of infertility or implantation failure (IVF) after in vitro fertilization is presently not recommended.
other autoantigens have been incriminated in APs pathophysiology

Biological aspects of antiphospholipid syndrome:
when and what to test? To test or not to test? Since aPL are found in 1% to 5% of the general population, there is no indication for aPL testing in asymptomatic pregnant women, especially since aPL assays have a high rate of false-positive results. 31 Testing for aPL should be performed in patients as detailed in TABLE 4. Since the presence of aPL can be transient, once a positive result is found, it should be repeated 12 weeks later to confirm the result and consider a diagnosis of APS.
TABLE 4 When to test antiphospholipid antibodies in obstetrics?
-APS patient when planning to get pregnant -pregnant patient with systemic lupus erythematous other autoimmune diseases -patient with a history of: -2-3 fetal losses <10 WG not due to causes described in There is still no indication for treating patients with a history of infertility or implantation failure after IVF and the presence of aPL. 30 However, our general practice shows that aPL can be commonly tested in this context, leading to management problems.
First-line treatment The current recommended therapeutics combine daily LDA beginning when the pregnancy is wanted with injection of LMWH injections to be started once pregnancy test is positive. Danowski et al.
10 recently established guidelines for APS treatment, and showed that there was no difference in managing APS in pregnant women with a history of recurrent early miscarriages or late fetal loss. However, our recent study showed that women with prior fetal losses treated with both molecules during pregnancy had lower early fetal loss rates but higher late complications such as PE compared with control women and APS women with recurrent early miscarriages only, suggesting that pathogenic mechanisms of aPL during pregnancy need to be better understood.
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In the absence of treatment, only 20% of pregnancies will develop positively. Treatment with early fetal loss. 37 Recently, the Global Anti-Phospholipid Syndrome Score was determined as a risk score for thrombosis and fetal loss in SLE patients, taking into account aPS and antiprothrombin (aPS-PT) antibodies as important predictors for aPL clinical complications. 38 Akhter et al. 35 also corroborated this study for anticoagulated SLE patient in whom lupus anticoagulant assays could not be used to predict an increased risk of thrombosis.
Management of obstetrical antiphospholipid syndrome
general considerations Pregnancy is not contraindicated in women with APS. Multidisciplinary counselling with obstetricians, hematologist, general practitioners, and immunologists should be performed to plan the pregnancy and determine the risks for both mother and fetus.
2-3 FIguRE 1 describes the general management of obstetrical APS. All risk factors for thrombosis should be avoided. During pregnancy and postpartum period, close follow-up should be performed with clinical examinations, ultrasound assessments, and determination of the tolerance, the efficacy, and the eventual side effects of treatments. Abbreviations: CAPS -catastrophic antiphospholipid syndrome, HCQ -hydroxychloroquine, IUGR -intrauterine growth restriction, TNF-α -tumor necrosis factor-α model and also in a few case reports. 15 However, these studies focused on their efficacy on thrombotic APS and CAPS (TABLE 5) rather than pregnancy, so their efficacy and safety during pregnancy still need to be determined and, therefore, clinical trials are required. the recommended therapeutics of APS during pregnancy increases the chance of completing a full-term pregnancy by 70%. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS) has shown that this first-line treatment is correctly administered according to actual guidelines in 87.1% of pregnant APS patients. 40 FIguRE 1 summarizes the first-line management of obstetrical APS. 41 First-line treatment has a few minor side-effects for the mother such as bruises and mild haematomas. Mild pain at LMWH injection sites may also be present. 42 To date, no side effects for the fetus have been reported. For APS patient already under oral anticoagulant (especially those with previous thrombosis history) such as warfarin, they may be switched to full-dose LMWH immediately after pregnancy confirmations because of the risk of teratogenicity of vitamin K antagonist (VKA).
10 VKA could be started again after delivery, as babies should receive oral vitamin K if breastfeeding.
second-line treatment Second-line treatments for APS pregnancies (or "refractory obstetric APS") are often a combination of first-line treatments with more aggressive therapy. To date, no consensus have been established and these treatments are proposed essentially on a case-by-case basis. 12 Available drugs are described in TABLE 5. Among them, HCQ is the safest one. 43 This molecule is used for the reduction of flares in lupus patients and is also commonly used in secondary APS associated with SLE. It has also been shown to be effective in the prevention of fetal loss and complications, especially in patients with anti-SSA and anti-SSB antibodies. [13] [14] Although high obstetrical morbidities were described in a study, treatment with low dose of prednisolone during first trimester pregnancies (n = 18) in refractory aPL-related pregnancy loss showed a decrease in fetal loss from 30% to 9%. 44 Since no well-designed trials have been conducted on all the secondary treatments listed in TABLE 5, careful precautions should be taken prior to their administrations. special considerations: preventing catastrophic antiphospholipid syndrome The best admitted treatment for CAPS is based on its prevention, therefore, postpartum period should be covered with 6 weeks of anticoagulation. 25 Once CAPS has been diagnosed, despite the lack of good studies on the treatment and the management of this entity, combined aggressive therapies, for example, with anticoagulants, corticosteroids, plasmapheresis, and rituximab are usually admitted as beneficial. Despite this, CAPS is still lethal in 50% of the cases.
Perspectives Immunomodulatory therapies, such as B-cell targeted therapies, anti-cytokines therapies and complement inhibition have shown their potential in vitro and in vivo in APS animal
